An experimental cholesterol-lowering drug from a new class of medications focused on taking a bite out of the billion-dollar statin market has outperformed Zetia, the most widely used alternative to statins on the market, according to a clinical trial presented at the American Heart Association annual meeting. Alirocumab drove down LDL, or bad, cholesterol levels in study participants by 45 percent, compared to just 14.6 percent in patients who were treated with Zetia. The main drawback is that alirocumab is administered by injection once every two weeks, while Zetia and statins are take by mouth in the form of a pill. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.